Tafasitamab (TAFA) Plus Lenalidomide (LEN) Prior to Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Relapsed/ Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Case Series of 8 Patients

被引：1
|
作者：
Veeraputhiran, Muthu [1 ]
Mehta, Amitkumar [2 ]
Alencar, Alvaro J. [3 ]
Modi, Dipenkumar [4 ]
Voorhees, Timothy J. [5 ]
Narkhede, Mayur [2 ]
机构：
[1] Univ Arkansas Med Sci, Winthrop P Rockefeller Canc Inst, Little Rock, AR 72205 USA
[2] Univ Albama, Birmingham, AL USA
[3] Univ Miami, Sylvester Canc Ctr, Miami, FL USA
[4] Karmanos Canc Ctr, Detroit, MI USA
[5] Ohio State Univ, Columbus, OH 43210 USA
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-158595
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：12089 / 12091
页数：3
相关论文
共 50 条
  • [1] Real-world outcomes of elderly patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated with chimeric antigen receptor T-cell (CAR-T) therapy.
    Fitzgerald, Lindsey
    Kittai, Adam
    Nastoupil, Loretta J.
    Waller, Alexandra
    Jacobson, Caron A.
    Saucier, Anna
    Kamdar, Manali K.
    Spradley, Janet
    Denlinger, Nathan
    Chipman, Jonathan
    Hu, Boyu
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [2] Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma
    Ernst, Moritz
    Oeser, Annika
    Besiroglu, Burcu
    Caro-Valenzuela, Julia
    Aziz, Mohamed Abd El
    Monsef, Ina
    Borchmann, Peter
    Estcourt, Lise J.
    Skoetz, Nicole
    Goldkuhle, Marius
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2021, (09):
  • [3] Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Patients: A Retrospective Analysis of Eligibility Criteria for CAR-T Cell Therapy
    Di Rocco, Alice
    Di Rocco, Arianna
    Farcomeni, Alessio
    Petrucci, Luigi
    De Luca, Giulia
    Mazzon, Federico
    Martelli, Maurizio
    Foa, Robin
    [J]. BLOOD, 2019, 134
  • [4] Radiotherapy Combined Chimeric Antigen Receptor T-Cells Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma(R/R DLBCL)
    Zhou, Lili
    Liu, Yifan
    Ye, Shiguang
    Li, Ping
    Li, Shaoguang
    Liang, Aibin
    [J]. BLOOD, 2023, 142
  • [5] CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY (CAR-T) UTILIZATION PATTERNS FOR RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) AMONG UNITED STATES (US) COMMUNITY HEMATOLOGISTS/ONCOLOGISTS (CH/OS)
    Feinberg, B.
    Klink, A.
    Schuler, T.
    Balanean, A.
    McAllister, L.
    Liassou, D.
    Gajra, A.
    Porter, D.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S322 - S322
  • [6] Therapeutic effects of chimeric antigen receptor T cells (CAR-T) on relapse/refractory diffuse large B-cell lymphoma (R/R DLBCL): a meta-analysis
    Cao, H-H
    Wang, L-L
    Geng, C-K
    Mao, W-W
    Yang, L-L
    Ma, Y.
    He, M.
    Zhang, R.
    Zhou, Y-Y
    Liu, L-Q
    Hu, X-J
    Yu, J-X
    Yang, L.
    Shen, X-F
    Yin, L-F
    Gu, X-Z
    Shen, Z-L
    [J]. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2020, 24 (09) : 4921 - 4930
  • [7] Impact of Tisagenlecleucel Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Attributes on Clinical Outcomes in Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL)
    Bachanova, Veronika
    Tam, Constantine S.
    Borchmann, Peter
    Jaeger, Ulrich
    McGuirk, Joseph P.
    Holte, Harald
    Waller, Edmund K.
    Jaglowski, Samantha
    Bishop, Michael R.
    Andreadis, Charalambos
    Foley, Stephen Ronan
    Westin, Jason R.
    Fleury, Isabelle
    Ho, P. Joy
    Mielke, Stephan
    Teshima, Takanori
    Salles, Gilles
    Schuster, Stephen J.
    Maziarz, Richard T.
    Van Besien, Koen
    Izutsu, Koji
    Kersten, Marie Jose
    Magenau, John M.
    Wagner-Johnston, Nina D.
    Kato, Koji
    Corradini, Paolo
    Chu, Jufen
    Gershgorin, Irina
    Choquette, Therese
    Pacaud, Lida Bubuteishvili
    Jeschke, Margit
    [J]. BLOOD, 2019, 134
  • [8] Real-World Treatment Patterns and Costs of Chimeric Antigen Receptor (CAR) T Cell Therapies, Polatuzumab Vedotin-Piiq (Pola), and Tafasitamab-Cxix (Tafa) in Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Liu, Fei Fei
    Subbiah, Krishnaveni
    Gu, Tao
    Le, Trong Kim
    [J]. BLOOD, 2022, 140 : 2414 - 2415
  • [9] Analysis of Patterns of Failure and the Role of Bridging Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Treated with CAR T-Cell Therapy
    Ravella, R.
    Zhang-Velten, E. R.
    Awan, F.
    Rizvi, S.
    Shah, J. L.
    Desai, N. B.
    Geethakumari, P. Ramakrishnan
    Kumar, K. A., Jr.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : E305 - E306
  • [10] COMPLETENESS OF REAL-WORLD DATA (RWD) IN CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY (CAR-T) FOR RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) IN UNITED STATES (US) COMMUNITY ONCOLOGY/HEMATOLOGY PRACTICES (CH/OS)
    Feinberg, B.
    Klink, A.
    Balanean, M. P. H. A.
    Schuler, T.
    McAllister, L.
    Liassou, D.
    Gajra, A.
    Porter, D.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S304 - S304
12345